A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
Phase of Trial: Phase III
Latest Information Update: 27 Mar 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Brentuximab vedotin
- Indications Hodgkin's disease
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-204
- Sponsors Merck Sharp & Dohme
- 15 Dec 2017 Planned End Date changed from 19 Dec 2019 to 31 Jul 2020.
- 15 Dec 2017 Planned primary completion date changed from 28 May 2018 to 30 Dec 2018.
- 13 Feb 2017 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.